pediatric liver transplantation has increased in all age ranges. 1 However, there has also been a relative increase in vascular complications following anastomoses involving small structures in transplant recipients.
1,4-6 Additionally, biliary atresia, the leading indication for transplantation in children, is associated with portal vein sclerosis, which may compound the difficulties during vascular reconstruction.
3
Portal vein stenosis and thrombosis after liver transplantation may be asymptomatic or associated with a variety of clinical manifestations, such as ascites, variceal bleeding, splenomegaly, changes in liver function tests, and low platelet count. 5, 7 In cases of portal vein stenosis, percutaneous transhepatic angioplasty (PTA) is considered the first line of treatment and has produced highly successful results. 1,2,7-9 However, 28%-50% of these patients may develop recurrent stenosis, 1, 10, 11 and stent placement has been an option to reduce this complication. 8, 12 In patients with chronic (> 1 month) portal vein thrombosis (PVT), recanalization of the portal vein using the percutaneous transhepatic approach is difficult, precluding venoplasty. 11, 13 In these patients, the failure rate can be as high as 75%. 13 When percutaneous venous angioplasty fails, treatment options are conservative measures (sclerotherapy), surgical bypass, and retransplantation.
13,14
This study aimed to retrospectively evaluate the long-term effectiveness of transmesenteric portal vein recanalization (PVR) with stent placement for chronic PVT in children undergoing liver transplantation. Demographic, clinical, and imaging data were collected from the medical records. The institutional review boards of both hospitals approved the study (CAAE protocol no. 53796416.0.0000.5432 and CAAE protocol no. 53796416.0.3001.5461), and informed consent was obtained from the children's relatives. portal vein of the liver graft. The vascular graft options were the living donor inferior mesenteric vein (n = 3), the recipient's internal jugular vein (n = 1), and fresh deceased-donor iliac artery (n = 12) or vein (n = 1) ( Table 1) . Details on donor selection and surgical techniques have been described previously. 
| MATERIAL S AND ME THODS
From
| Recipient portal vein reconstruction at the time of liver transplantation

| PVR technique and postprocedure management
All patients with suspected PVT underwent triphasic upper abdominal CT scanning to characterize the intrahepatic portal vein, the superior mesenteric vein, and the splenic vein. In the operating room, the children underwent angiography under general anesthesia using a portable angiography system. PVR was performed via the transmesenteric route in all cases, with or without previous percutaneous transhepatic access. At the beginning of our series (until patient no. 13), the percutaneous transhepatic approach was used before the minilaparotomy because it was the first choice of access to the portal vein in the literature. However, because of the high failure rate in PVR attempts, the percutaneous transhepatic techniques were abandoned, and the transmesenteric route became the only approach used in the remaining participants.
We used the transmesenteric approach via minilaparotomy to access an upper/lower mesenteric vein or its tributaries. The children were maintained on low-molecular-weight heparin (2 mg/kg), followed by oral anticoagulation with warfarin to maintain the international normalized ratio between two and three times the control levels for at least 3 months. US surveillance was performed on day 1 after the procedure, and then in months 1, 3, 6, and 12 and every year thereafter. CT angiography was ordered in cases of abnormal US findings (increase in systolic peak velocity in the portal anastomosis and presence of poststenotic dilatation of the portal vein). Direct portography was performed when necessary. 
| Statistical analysis
| RE SULTS
At the time of transplantation, patient age ranged from 5.9 months to 3.4 years (median, 8.6 months), and body weight ranged from 5.0 to 11.9 kg (median, 6.7 kg) ( Table 1) . Indications for liver transplantation were biliary atresia (n = 27) and choledochal cyst (n = 1). The children either received left lateral segments from living donors (n = 26) or underwent split-liver transplantation (n = 2). The median graft-to-recipient weight ratio was 4.4% (range, 2.1-6.9%), and the median portal vein diameter was 4 mm (range, 3.0-5.6 mm) ( Table 1 ).
The different types of portal vein reconstruction and fresh vascular grafts used are shown in Table 1 .
The clinical manifestations of chronic PVT included GIB in 10 patients (34.6%), hypersplenism (splenomegaly and platelet count below 100,000/mm 3 ) in 21 patients (61.5%), ascites in 8 patients (26.9%), and esophageal varices in 11 patients (39.3%) ( Table 1) . After US examination, 13 patients were diagnosed with PVT and 2 with stenosis, and 13 had a patent portal vein. After CT angiography/MRI, the diagnosis was PVT in 26 patients and stenosis in 2 patients; none of the patients had a patent portal vein.
Direct portography confirmed PVT in all cases (Table 1) . Doppler US provided the correct diagnosis in 46.4% of cases, whereas CT/MRI provided the correct diagnosis in 92.8% of cases.
The median time between the diagnosis of PVT and living-donor liver transplantation was 17.3 months (range, 1.3-91 months). The diagnosis of PVT occurred within the first 6 months in 3 patients, between 6 months and 1 year in 4 patients, between 1 year and 2 years in 11 patients, between 2 and 3 years in 3 patients, between 3 and 5 years in 3 patients, and after 5 years in 4 patients. Considering all cases of PVT after 6 months (n = 25), vein grafts were used in 15 patients (deceased-donor iliac arteries in 11), and direct portal vein anastomosis was performed in 10 patients.
PVR via minilaparotomy was attempted in all 28 patients (Figure 2 ). At the time of intervention, patient median age was 2.7 years (range, 8.1 months to 11.8 years) and body weight was 14.9 kg (range, 5.5-37 kg) ( Table 2 ). The interval between the diagnosis of PVT and PVR ranged from 0 to 67.6 months (median, 3.5 months). The time elapsed between diagnosis and PVR was less than 1 year in 22 patients, between 1 year and 2 years in 2 patients, between 2 and 3 years in 1 patient, between 3 and 5 years in 1 patient, and more than 5 years in 2 patients (Table 2) .
Twenty-two patients underwent successful PVR and stent placement using the minilaparotomy approach (with or without transhepatic access), with technical success of 78.6%. In six patients (21.4%), recanalization was not possible, requiring conservative management using endoscopic ligation of gastroesophageal varices. The interval between the diagnosis and the procedure was < 1 year in four patients and > 1 year in two patients. Surgical intervention was required in three patients with persistent GIB, with the placement of a surgical portosystemic shunt in two patients and a Meso-Rex shunt in one patient. The procedures were successful, but the shunts thrombosed during follow-up (less than 6 months) in two patients in whom fresh vascular grafts were used.
All treated children received oral anticoagulants for at least 3 consecutive months after the procedure, and the clinical symptoms subsided. The children remained hospitalized for anticoagulation for an average of 5 days.
There was no procedure-related mortality, but one child had symptoms of sepsis in the immediate postoperative period, probably due to bacterial skin contamination during surgery. This was completely resolved with antibiotic therapy. There were no other shortor long-term procedure-related complications during follow-up.
Two patients died during the follow-up period. One died becuase of rejection at 3.2 months after the procedure, and one patient with GIB, probably secondary to PVT, died at 5.2 months after the procedure (oral anticoagulant therapy had been discontinued after 3 months). In the latter case, the child was evaluated in another hospital and we did not have access to all examinations; because of that, the patient was excluded from the retreatment analyses.
| Restenosis/thrombosis
During follow-up, restenosis/thrombosis occurred in 7 (31.8%) of the 22 patients who underwent successful PVR. Other interventions performed in these patients during follow-up are shown in Table 3 and Figure 3 . In two (28.6%) of these patients, restenosis was re- Figure 6A and 6B. Figure 6C shows the overall stent patency (in 5 years) since the first recanalization of PVT until the final occlusion, in which further recanalization was not possible (median, 25.7 months; excluding the patient who died 3.2 months after the procedure). Based on these curves, we can assume that 40% of patients will develop stent thrombosis at 30 months of follow-up.
However, further interventions may be performed, and more than 80% of them will have a patent portal vein in the same period. In 5 years, the overall stent patency rate was over 80%. PTA is the standard initial treatment for portal vein complications, and placement of vascular stents should be limited to cases of recurrence or balloon dilation of stenosis, particularly in children. 1,2,4,5,10-13 However, in cases of complete PVT, the failure rate can be as high as 75%. 13 The use of the transmesenteric access for PVR after transhepatic access failure has been described as an alternative successful approach, Another option is the transsplenic access, 8, 24, 25 which is less injurious to the transplanted liver graft. This route was successfully used in 2 cases of stent thrombosis to avoid a second laparotomy. It was also used in one case of chronic PVT, although it had to be combined with a transhepatic access, because the transsplenic access provided no adequate support to cross the occlusion. In this case, balloon dilation and stent placement were performed transhepatically. In the present series, all patients who had PVT were treated with stent placement to prevent recurrence.
TA B L E 2 PVR and post-PVR data
| D ISCUSS I ON
The interval between the diagnosis of portal vein occlusion and stenting is crucial for posttransplant management. 8 Early diagnosis and management of the portal vein obstruction were essential to achieve better treatment results in the study by Cheng et al. 8 Their success rate was 83.3% in patients with a diagnosis of complete PVT and transsplenic recanalization within 1 year, and 0% in patients with a diagnosis of complete PVT after 1 year. Most of our patients (78.5%) had less than 1 year of PVT, with an 81.8% technical success rate in this group, compared to a rate of 66.7% in patients with more than 1 year of PVT (two patients had more than 5 years of PVT, and the recanalization was still possible).
The use of anticoagulants after PVR and stent placement is controversial. We decided to use them during and for at least 3 months after the procedure because of the risk of thrombosis in the stented vein. There were no anticoagulation-related complications during follow-up. Sanada et al, 10 in a study on how to prevent recurrent portal vein stenosis following balloon dilation in pediatric liver transplantation, concluded that stronger anticoagulation is necessary to prevent recurrence of portal vein stenosis. They suggest the use of a three-agent anticoagulant therapy that combines low-molecularweight heparin, warfarin, and aspirin for 3 months. This combination regimen reduced portal vein stenosis recurrence from 55.6% to 0%
in long-term follow-up (from 9 to 47 months). In recent cases, we have extended anticoagulation to 6 months of warfarin anticoagulation, maintaining patients on oral aspirin thereafter.
On an intention-to-treat basis, the success rate of the proposed treatment (PVR) was 60.7%. Only 17 out of 28 children with posttransplant chronic PVT retained stent patency (primary + assisted)
at the end of the study period. Our experience shows that PVR using a transmesenteric approach may be an alternative procedure to reestablish the portal flow to the liver graft in selected cases. It is a therapeutic addition to other treatment strategies currently used to treat chronic PVT. It has acceptable technical and clinical success rates, long-term permeability, and a low rate of procedure-related complications. Despite the good technical and clinical success rates in this group of children, the study is limited by its retrospective nature and small number of patients. Nevertheless, other researchers should attempt to replicate these results to confirm the possible use of this procedure in this group of patients.
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